Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 1/2012

01.02.2012 | Chronic Daily Headache (SJ Wang, Section Editor)

Obesity and Chronic Daily Headache

verfasst von: Marcelo E. Bigal, Alan M. Rapoport

Erschienen in: Current Pain and Headache Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Obesity may be the greatest epidemic of modern times. It leads to diabetes and heart disease and shortens lifespan. Although not a risk factor for migraine, it is associated with an increased frequency and intensity of migraine. Obesity is also comorbid with chronic daily headache and is a major risk factor for chronification of episodic migraine in adults and children. Although obesity is not a factor in the effectiveness of migraine treatment, it does increase the peripheral and central events in migraine, ultimately increasing the neurologic potential for migraine. Although evidence suggests that obesity is a modifiable risk factor for migraine progression, it is unknown if weight loss is related to decrease in headache frequency. Recent surgical results suggest that this is true. We suggest all possible effective techniques aimed at weight loss be undertaken for migraineurs, especially obese migraineurs, and that carefully monitoring weight changes should be routinely done as part of their migraine care.
Literatur
1.
Gelber RP, Gaziano JM, Orav EJ, et al. Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol. 2008;52:605–15.PubMedCrossRef
2.
Tzamaloukas AH, Murata GH, Hoffman RM, et al. Classification of the degree of obesity by body mass index or by deviation from ideal weight. JPEN J Parenter Enteral Nutr. 2003;27:340–8.PubMedCrossRef
3.
•• National Center for Chronic Disease Prevention and Health Promotion. Overweight and obesity: obesity trends. Vol. 2011, 2011. This is a pivotal source of data on obesity from the Centers for Disease Control.
4.
Sturm R. Stemming the global obesity epidemic: what can we learn from data about social and economic trends? Public Health. 2008;122:739–46.PubMedCrossRef
5.
de Onis M, Blossner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr. 2010;92:1257–64.PubMedCrossRef
6.
Deurenberg P, Yap M. The assessment of obesity: methods for measuring body fat and global prevalence of obesity. Baillieres Best Pract Res Clin Endocrinol Metab. 1999;13:1–11.PubMedCrossRef
7.
Gurney M, Gorstein J. The global prevalence of obesity—an initial overview of available data. World Health Stat Q. 1988;41:251–4.PubMed
8.
Finkelstein EA, Fiebelkorn IC, Wang G. State-level estimates of annual medical expenditures attributable to obesity. Obes Res. 2004;12:18–24.PubMedCrossRef
9.
Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff (Millwood). 2003;Suppl Web Exclusives:W3-219-226.
10.
Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF). J Headache Pain. 2005;6:429–40.PubMedCrossRef
11.
Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.PubMedCrossRef
12.
13.
14.
Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45 Suppl 1:S3–S13.PubMedCrossRef
15.
Yunus MB, Arslan S, Aldag JC. Relationship between body mass index and fibromyalgia features. Scand J Rheumatol. 2002;31:27–31.PubMedCrossRef
16.
Webb R, Brammah T, Lunt M, et al. Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine (Phila Pa 1976). 2003;28:1195–202.
17.
McCarthy LH, Bigal ME, Katz M, et al. Chronic pain and obesity in elderly people: results from the Einstein aging study. J Am Geriatr Soc. 2009;57:115–9.PubMedCrossRef
18.
Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology. 2006;66:545–50.PubMedCrossRef
19.
Winter AC, Berger K, Buring JE, Kurth T. Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia. 2009;29:269–78.PubMedCrossRef
20.
Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81–9.PubMedCrossRef
21.
Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and CM: possible mechanisms of interaction. Neurology. 2007;68:1851–61.PubMedCrossRef
22.
Bigal ME, Tsang A, Loder E, et al. Body mass index and episodic headaches: a population-based study. Arch Intern Med. 2007;167:1964–70.PubMedCrossRef
23.
24.
Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf. 2002;25:467–71.PubMedCrossRef
25.
Recober A, Goadsby PJ. Calcitonin gene-related peptide: a molecular link between obesity and migraine? Drug News Perspect. 2010;23:112–7.PubMedCrossRef
26.
• Hershey AD, Powers SW, Nelson TD, et al. Obesity in the pediatric headache population: a multicenter study. Headache. 2009;49:170–7. This was the first study to demonstrate that obesity was associated with increased headache headache frequency in the pediatric population. PubMedCrossRef
27.
Kinik ST, Alehan F, Erol I, Kanra AR. Obesity and paediatric migraine. Cephalalgia. 2010;30:105–9.PubMed
28.
Tietjen GE, Peterlin BL, Brandes JL, et al. Depression and anxiety: effect on the migraine-obesity relationship. Headache. 2007;47:866–75.PubMedCrossRef
29.
• Peterlin BL, Rosso AL, Rapoport AM, Scher AI. Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache. 2010;50:52–62. This is a study addressing obesity factors associated with the obesity/migraine influence. PubMedCrossRef
30.
Bigal ME, Gironda M, Tepper SJ, et al. Headache prevention outcome and body mass index. Cephalalgia. 2006;26:445–50.PubMedCrossRef
31.
Bigal ME, Lipton RB, Biondi DM, et al. Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine. Cephalalgia. 2009;29:1188–96.PubMedCrossRef
32.
Bigal ME, Lipton RB. Putative mechanisms of the relationship between obesity and migraine progression. Curr Pain Headache Rep. 2008;12:207–12.PubMedCrossRef
33.
Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658–60.PubMedCrossRef
34.
Afridi S, Giffin NJ, Kaube H, et al. A PET study in spontaneous migraine. Arch Neurol. 2005;62:1270–5.PubMedCrossRef
35.
Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127:220–30.PubMedCrossRef
36.
Afridi S, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128:932–9.PubMedCrossRef
37.
Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet. 2001;357:1016–7.PubMedCrossRef
38.
Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987;27:416–20.PubMedCrossRef
39.
Veloso F, Kumar K, Toth C. Headache secondary to deep brain implantation. Headache. 1998;38:507–15.PubMedCrossRef
40.
Haas DC, Kent PF, Friedman DI. Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache. 1993;33:452–5.PubMedCrossRef
41.
Goadsby PJ. Neurovascular headache and a midbrain vascular malformation- evidence for a role of the brainstem in chronic migraine. Cephalalgia. 2002;22:107–11.PubMedCrossRef
42.
Afridi S, Goadsby PJ. New onset migraine with a brainstem cavernous angioma. J Neurol Neurosurg Psychiatry. 2003;74:680–2.PubMedCrossRef
43.
Obermann M, Gizewski ER, Limmroth V, et al. Symptomatic migraine and pontine vascular malformation: evidence for a key role of the brainstem in the pathophysiology of chronic migraine. Cephalalgia. 2006;26:763–6.PubMedCrossRef
44.
Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193–6.PubMedCrossRef
45.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–7.PubMedCrossRef
46.
Goadsby PJ. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs. 2005;65:2557–67.PubMedCrossRef
47.
Flier JS. The adipocyte: storage depot or node on the energy information superhighway? Cell. 1995;80:15–8.PubMedCrossRef
48.
Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology. 2007;132:2103–15.PubMedCrossRef
49.
Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200.PubMedCrossRef
50.
Mohamed-Ali V, Flower L, Sethi J, et al. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab. 2001;86:5864–9.PubMedCrossRef
51.
Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744–7.PubMedCrossRef
52.
Gram DX, Hansen AJ, Wilken M, et al. Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur J Endocrinol. 2005;153:963–9.PubMedCrossRef
53.
Altink ME, Slaats-Willemse DI, Rommelse NN, et al. Effects of maternal and paternal smoking on attentional control in children with and without ADHD. Eur Child Adolesc Psychiatry. 2009;18:465–75.PubMedCrossRef
54.
Peterlin BL, Bigal ME, Tepper SJ, et al. Migraine and adiponectin: is there a connection? Cephalalgia. 2007;27:435–46.PubMedCrossRef
55.
Peterlin BL, Alexander G, Tabby D, Reichenberger E. Oligomerization state-dependent elevations of adiponectin in chronic daily headache. Neurology. 2008;70:1905–11.PubMedCrossRef
56.
Peterlin BL. The role of the adipocytokines adiponectin and leptin in migraine. J Am Osteopath Assoc. 2009;109:314–7.PubMed
57.
Kondo M, Shibata R, Miura R, et al. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem. 2009;284:1718–24.PubMedCrossRef
58.
Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6–25.PubMedCrossRef
59.
Estabrooke IV, McCarthy MT, Ko E, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci. 2001;21:1656–62.PubMed
60.
Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437–51.PubMedCrossRef
61.
Bingham S, Davey PT, Babbs AJ, et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain. 2001;92:81–90.PubMedCrossRef
62.
Cheng JK, Chou RC, Hwang LL, Chiou LC. Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain. J Pharmacol Exp Ther. 2003;307:1065–71.PubMedCrossRef
63.
Kajiyama S, Kawamoto M, Shiraishi S, et al. Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res. 2005;1044:76–86.PubMedCrossRef
64.
Yamamoto T, Saito O, Shono K, et al. Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model. Neurosci Lett. 2003;347:183–6.PubMedCrossRef
65.
Baranowska B, Wolinska-Witort E, Martynska L, et al. Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol Lett. 2005;26:293–6.PubMed
66.
Smart D. Orexins: a new family of neuropeptides. Br J Anaesth. 1999;83:695–7.PubMed
67.
Overeem S, van Vliet JA, Lammers GJ, et al. The hypothalamus in episodic brain disorders. Lancet Neurol. 2002;1:437–44.PubMedCrossRef
68.
Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005;315:1380–5.PubMedCrossRef
69.
Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46:1334–43.PubMedCrossRef
70.
Sidhaye A, Cheskin LJ. Pharmacologic treatment of obesity. Adv Psychosom Med. 2006;27:42–52.PubMedCrossRef
71.
• Young WB. Preventive treatment of migraine: effect on weight. Curr Pain Headache Rep. 2008;12:201–6. This is an interesting review of the effects of preventive medication on weight. PubMedCrossRef
72.
Peterlin BL, Calhoun AH, Siegel S, Mathew NT. Rational combination therapy in refractory migraine. Headache. 2008;48:805–19.PubMedCrossRef
73.
Novack V, Fuchs L, Lantsberg L, et al. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series. Cephalalgia. Published online 23 June 2011.
74.
Lee PB. Bariatric surgery in obese migraineurs: mounting evidence but important questions remain. Cephalalgia. 2011;31:1333–5.CrossRef
75.
Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67:252–7.PubMedCrossRef
Metadaten
Titel
Obesity and Chronic Daily Headache
verfasst von
Marcelo E. Bigal
Alan M. Rapoport
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Pain and Headache Reports / Ausgabe 1/2012
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-011-0232-0

Weitere Artikel der Ausgabe 1/2012

Current Pain and Headache Reports 1/2012 Zur Ausgabe

Chronic Daily Headache (SJ Wang, Section Editor)

Pathophysiology of Medication-overuse Headache: Implications from Animal Studies

Anesthetic Techniques in Pain Management (GJ Brenner, Section Editor)

Spinal Cord Stimulation: A Review

Chronic Daily Headache (SJ Wang, Section Editor)

Controversy over the Classification of Medication-Overuse Headache

Chronic Daily Headache (SJ Wang, Section Editor)

Chronic Daily Headache in Children and Adolescents

Invited Commentary

Ethical Challenges and Interventional Pain Medicine

Anesthetic Techniques in Pain Management (GJ Brenner, Section Editor)

Radiofrequency Treatment of Facet-related Pain: Evidence and Controversies

Neu im Fachgebiet AINS

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise